structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics to Present at Jefferies Healthcare Conference
31 mai 2023 16h30 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
25 mai 2023 16h30 HE | Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
18 mai 2023 16h30 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 mai 2023 16h30 HE | Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
30 mars 2023 16h30 HE | Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
Offshore Wind Indust
Offshore Wind Industry Power Players Headline 2023 IPF
29 mars 2023 19h26 HE | Business Network for Offshore Wind
Baltimore, March 29, 2023 (GLOBE NEWSWIRE) -- Exactly two years after President Biden announced a national target to deploy 30 GW of offshore wind energy capacity by 2030, key government and...
Media Advisory: Inte
Media Advisory: Interior Secretary Haaland, White House Climate Advisor Zaidi, Maryland Governor Moore to headline major offshore wind conference
27 mars 2023 10h03 HE | Business Network for Offshore Wind
Baltimore, March 27, 2023 (GLOBE NEWSWIRE) -- The tenth annual International Offshore Wind Partnering Forum (IPF), hosted by the Business Network for Offshore Wind, will kick off this Tuesday, March...
Interior Secretary H
Interior Secretary Haaland, White House Climate Advisor Zaidi, Maryland Governor Moore to Headline 2023 International Offshore Wind Partnering Forum
14 mars 2023 08h30 HE | Business Network for Offshore Wind
Baltimore, March 14, 2023 (GLOBE NEWSWIRE) -- The Business Network for Offshore Wind today announced U.S. Secretary of the Interior Deb Haaland, White House National Climate Advisor Ali Zaidi, and...
logo.jpg
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
24 févr. 2023 07h30 HE | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
17 févr. 2023 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....